Clinical Trial Update: A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2 [Phase 3]

View source ↗

Summary

Phase 3 randomized trial evaluating whether Nystatin reduces oral irritation in patients receiving high-dose intravenous interleukin-2; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Diseases
• Oral Candidiasis
• Stomatitis

Drugs mentioned

• Nystatin (Nystatin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Candidiasis, Oral, Gastrointestinal Diseases | Phase 3 | Status: COMPLETED